CMAB Biopharma of Suzhou Announces $34 Million Series B
publication date: Apr 2, 2018
CMAB Biopharma of Suzhou announced a Series B of $34 million led by CDBI Partners, with C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed participating. The funds will be used to equip a GMP manufacturing facility compliant with China, US, EU and ICH standards. Three months ago, CMAB raised $38 million in a Series A funding led by C-Bridge Capital and BioBAY Park.The facility will contain production, purification and injection filling lines with reactors varying from 50L to 2000L, aiming to provide CDMO services for global clients in Phase I/II trials. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.